The 2026 VA/DoD clinical guideline recommends varenicline and combination NRT as preferred tobacco cessation treatments, shifting focus to medical care.
In September 2026, the U.S. Department of Veterans Affairs and the Department of Defense issued an updated clinical practice guideline for treating tobacco and nicotine use among adults. The document was carefully developed by a multidisciplinary VA/DoD panel that reviewed research published from 2014 through 2024. The resulting document contains 32 explicit recommendations covering cessation medications, clinical counseling methods, and practical treatment strategies for adults using different tobacco and nicotine products. The guideline clearly identifies varenicline and combination nicotine replacement therapy as preferred treatments to increase total tobacco abstinence. Combination therapy typically involves a long acting nicotine patch carefully paired with a short acting product like gum or lozenges.
The medical implications of these new guidelines extend far beyond simply breaking a daily habit. Tobacco and nicotine use directly impacts cardiovascular health, respiratory function, and overall physical resilience. Medical reports continue to link tobacco and nicotine use among service members and veterans with severe physical and mental health effects. These health impacts can rapidly result in reduced force readiness across the entire military community. The new guidance provides a structured medical framework for addressing these exact challenges through evidence based treatment.
At BattleVet, we know firsthand that physical performance and daily function require proactive maintenance over time. I remember waking up after a poor night of sleep and realizing that my training recovery was taking much longer than it used to. I realized that readiness is more than just pushing through the fatigue. It requires a dedicated approach to sleep and hormonal health, which completely shifted how I view long term capability. Nicotine use requires a similarly serious approach to overall recovery and health management. Treating it as a medical condition rather than a simple lack of willpower changes the entire trajectory of patient care.
The updated guideline expands its focus beyond combustible cigarettes to include adults using a variety of tobacco and nicotine products. This is highly relevant for active duty personnel and veterans who may use smokeless tobacco or other nicotine alternatives in the field. By establishing preferred medical treatments, the VA and DoD are standardizing the baseline of care across all military and veteran health systems. This focused effort ensures that veteran healthcare remains grounded in the most current research available.
The clinical shift toward specific pharmacological interventions is backed by distinct medical trials and recent evidence summaries. A 2026 American Academy of Family Physicians evidence summary analyzed data specifically for smokeless tobacco cessation. The detailed summary reported that varenicline improved cessation compared with placebo at six months or later. This specific finding showed a risk ratio of 1.35 and an absolute risk difference of 11.6 percent.
The varenicline estimate came directly from two randomized trials involving 508 total participants. These trials yielded a number needed to treat of 9. This statistical metric is used in medicine to indicate how many patients need to receive an intervention for one to see a positive outcome. A lower number needed to treat generally points to a highly effective clinical intervention.
The 2026 summary also evaluated nicotine replacement therapy specifically for smokeless tobacco users. The data showed that nicotine replacement therapy improved cessation compared with placebo or no medication. For this treatment pathway, the summary noted a risk ratio of 1.18 and an absolute risk difference of 5 percent. This estimate was drawn from 11 randomized trials involving 2,826 total participants, resulting in a number needed to treat of 20.
These concrete figures illustrate the measurable clinical benefits of using proper cessation medications over unassisted attempts. The data reinforces the central clinical judgment that these specific medications should be prioritized in clinical settings. The ultimate goal is increasing total long term abstinence among patients.
Pharmacists are currently playing an increasingly large role in delivering these exact treatments within the VA system. As medical guidelines shift toward pharmacological solutions, pharmacy teams manage a significant portion of patient care. A 2026 American Journal of Health-System Pharmacy article reported on the specific distribution of cessation prescriptions. Pharmacy clinicians accounted for approximately 30 percent of VHA prescriptions for varenicline, nicotine nasal spray, and nicotine inhalers in 2020. They managed this substantial volume while representing only 14 percent of all VHA prescribers during that exact period.
The VA and DoD recommendations fundamentally change how patients and clinicians should approach modern tobacco treatment. Previously, some individuals might have relied solely on counseling or pure willpower to stop using nicotine products. The VA Maryland Tobacco Treatment Clinic explicitly notes that counseling alone does not effectively treat tobacco use disorder. A clinician quoted in the VA Maryland report stated clearly that pharmacotherapy is a crucial component of complete treatment.
Dr. Conklin, a physician at the VA Maryland clinic, explained that the VA offers veterans a truly comprehensive approach. This updated approach involves personal treatment plans, dedicated counseling, clinical education, and specific medicines. The process is highly individualized to meet the specific physiological needs of each unique patient. Veterans looking to access these specialized clinical resources must specifically request a referral from their primary provider to participate in the clinic program.
The integration of targeted medication into standard treatment plans is now a clear priority in military health. This structured system ensures that personnel receive appropriate clinical oversight rather than trying to manage complex physical dependencies independently.
The updated guideline introduces critical shifts in how clinicians handle patient engagement and inevitable relapses. It heavily recommends motivational interviewing to improve overall patient engagement in cessation treatment. Clinicians are explicitly encouraged to offer treatment even when a patient is not yet completely ready to quit. The guidance recommends immediate retreatment after relapse rather than treating a return to tobacco use as a medical failure.
This modern continuous care model keeps patients firmly connected to their treatment providers even during temporary setbacks. It ensures that a behavioral relapse triggers renewed medical support instead of leading to exclusion from ongoing care programs.
One of the most important shifts in the new guideline directly addresses patients with existing mental health diagnoses. The guideline specifically emphasizes that pharmacotherapy can be safe and effective for people with co-occurring mental health conditions. This is a vital medical clarification for the entire veteran community. It rejects the outdated implication that a co-occurring mental health condition automatically rules out pharmacological cessation treatment.
Service members and veterans dealing with depression or anxiety should not assume these medications are universally unsafe. They should discuss their complete medical history directly with their military or civilian provider. Medication safety in people with mental health conditions always requires proper clinically supervised treatment. It is not a guarantee that adverse effects cannot occur, but it establishes a secure pathway to effective care.
The guideline recommends combination nicotine replacement therapy as a highly preferred treatment option. This approach typically involves pairing a daily long acting nicotine patch with a short acting product like gum. However, combination nicotine replacement therapy should never be confused with combining varenicline and replacement therapies together. The medical safety of combining varenicline with nicotine replacement therapies is not established in current reviews.
Varenicline remains a strict prescription treatment that requires exact adherence to a specific daily schedule. DailyMed labeling states that varenicline is generally prescribed for a standard 12 week duration. An additional 12 week course is recommended for people who have successfully stopped smoking at the end of the initial course. This extended timeline is specifically designed to support long term abstinence and actively prevent future relapses.
Patients must follow the official prescribing information and clinician instructions rather than self designing a dosage regimen. Service members should use official medical channels to discuss their cessation medication thoroughly. This is incredibly important when deployment schedules, sleep issues, or other prescribed medicines may affect the treatment plan. Proper clinical assessment remains absolutely necessary to review current medications, dependence patterns, and any possible medical contraindications.
As clinical frameworks continue to evolve over time, integrating these targeted medical treatments into routine veteran life could significantly reduce long term physical health risks. The definitive shift toward immediate retreatment and continuous clinical engagement reflects a more realistic understanding of addiction recovery. How will this modern chronic care model ultimately shape the next generation of veteran health policies and future clinical practice guidelines?
Follow BattleVet for practical guidance on military and veteran health, strength, recovery, testosterone, sleep and healthy aging. Stay connected for new articles, research backed insights and clear information to help you stay capable for the years ahead.
Andrew Huberman shared a weekly workout plan for staying capable after 50. Learn how veterans can adapt this fitness framework for long-term healthy aging.
The VA processed over 3 million disability claims in fiscal year 2026. Read how updated decision timelines and evidence rules impact veteran healthcare access.
The U.S. Army highlights carbohydrates and adequate calories as practical field guidance for sustaining soldier performance during high altitude operations.
Build better habits around strength, recovery, sleep, hormones and healthy aging with practical guidance for active military personnel and veterans.
Explore BattleVet